SEC Tracker
Get the app

Alaunos Therapeutics TCRT

Alaunos Therapeutics: Ownership stake disclosure (amended)

Ownership stake disclosure by Adrian Price (amended)

Form
Schedule 13D/A
Filed
Importance
Notable
  1. Reporting persons include Chris Butterworth, Richard Jones, and others.
  2. Each reporting person used personal funds for the transaction.
  3. The purpose is to discuss creating shareholder value with the board.
  4. The reporting persons may suggest nominees for strategic acquisitions.

Written from the Schedule 13D/A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Alaunos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. BioCardia BCDA public float $10M, Jun 30, 2025
  2. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025
  3. Traws Pharma ONTX public float $10M, Jun 30, 2025
  4. Mannatech MTEX public float $10M, Jun 30, 2025
  5. Bioxytran BIXT public float $9M, Jun 30, 2025